Last-Resort drug made available for Tough-to-Treat melanoma
NCT ID NCT06063746
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program offers vidutolimod (CMP-001) to people with refractory melanoma who have run out of standard options. It is a compassionate use access, not a clinical trial, so it is only available when no other treatments are left. The goal is to provide a potential therapy for those with few choices.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Vidutolimod (CMP-001)
- What this could lead to
- If it works, this could offer a treatment option for people with melanoma that hasn't responded to other therapies.
- What could go wrong
- This is a compassionate use program, not a formal trial, so there is no controlled data on how well it works or its risks. It may not help everyone, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New combo tackles tough melanoma
- Experimental melanoma combo trial shutters after just one patient
- New vaccine trains immune system to fight tough melanoma
- New cocktail of cancer drugs targets brain metastases in melanoma patients
- Supercharged immune cells take on hard-to-treat melanoma in early trial
- New cancer drug IACS-6274 enters early human testing